Trials / Unknown
UnknownNCT04122339
MAX-10181 Given Orally to Patients With Advanced Solid Tumor
A Phase I Study of MAX-10181 Given Orally to Patients With Advanced Solid Tumor
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Maxinovel Pty., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, first-in-human, non-randomized, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-10181 in patients with advanced solid tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MAX-10181 | Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria. Part 2: Dose expansion, Recommended doses from Part 1. |
Timeline
- Start date
- 2020-02-11
- Primary completion
- 2022-10-01
- Completion
- 2022-11-01
- First posted
- 2019-10-10
- Last updated
- 2022-01-19
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT04122339. Inclusion in this directory is not an endorsement.